Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Spain
/
Pharmaceuticals & Biotech
/
Grifols
GRF
Grifols
Emerging Markets And Aging Populations Will Drive Plasma Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 13 Analysts
Published
22 Jun 25
Updated
08 Aug 25
2
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
€24.00
46.0% undervalued
intrinsic discount
08 Aug
€12.96
Loading
1Y
47.7%
7D
0.2%
Author's Valuation
€24.0
46.0% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
€24.0
46.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-5m
9b
2014
2017
2020
2023
2025
2026
2028
Revenue €9.1b
Earnings €1.2b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.85%
Biotech revenue growth rate
10.70%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
9.89%
Calculation
€1.16b
Earnings '28
x
18.72x
PE Ratio '28
=
€21.77b
Market Cap '28
€21.77b
Market Cap '28
/
680.18m
No. shares '28
=
€32.01
Share Price '28
€32.01
Share Price '28
Discounted to 2025 @ 9.87% p.a.
=
€24.13
Fair Value '25